Prices are updated after-hours

Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

published : Today    tags : Trial    exchanges : Nyse    save search

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
NVO | News | $124.53 0.88% 0.0% 2.6M twitter stocktwits trandingview |
Health Technology
| | O: 1.27% H: 0.0% C: 0.0%

vent-02 trial therapeutics results
Gainers vs Losers
56% 44%

Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M twitter stocktwits trandingview |
Health Technology

SINT | $0.0365 59.39% 37.26% 470M twitter stocktwits trandingview |
Health Technology

WISA 4 | $9.19 50.66% 33.7% 65M twitter stocktwits trandingview |
Electronic Technology

EDBL | News | $6.73 47.91% 32.39% 13M twitter stocktwits trandingview |

GCTK | $0.715 36.27% 26.62% 640K twitter stocktwits trandingview |
Manufacturing

TCON | $2.33 36.26% 26.61% 2M twitter stocktwits trandingview |
Health Technology

TIRX | $0.48 6.43% 24.58% 4.8M twitter stocktwits trandingview |

KZIA | $0.38 30.58% 23.42% 300K twitter stocktwits trandingview |
Health Technology

VNDA | News | $5.23 29.14% 22.56% 24M twitter stocktwits trandingview |
Health Technology

ATNF | $1.91 29.05% 22.51% 310K twitter stocktwits trandingview |


Your saved searches
Save your searches and get alerts when important news are released.